אמבוטרה 25 מ"ג - Amvuttra 25 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× |
|
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | N07XX Other nervous system drugs |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | תת-×¢××¨× - S.C |
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Amvuttra is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. |
| ×ת××ת ××× ×× | Posology and method of administration |
| ×ת××××ת × ×× | Contraindications |
| ת×פע×ת ××××× | Undesirable effects |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××××¨× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ALNYLAM NETHERLANDS B.V., THE NETHERLANDS |
| ×©× ××¢× ×ר×ש×× | MEDISON PHARMA LTD |
| ר×ש××× | ת×ר×× ××ש×: 5/2023. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 06/08/2024 |
השינוי האחרון נעשה בֹ־4 באוקטובר 2024 ב־03:20